Make sure this course is right for you.
Get unbiased reviews and personalized recommendations.
Who should attend
The program is designed for global market access managers interested in enhancing their understanding of the complexities in market access in LMICs and engaging with their peers.
About the course
Access to medicines in low- and middle-income countries (LMICs) is a complex challenge and there is no ‘one size fits all solution. It requires deep understanding of the context, actors, economics and operational functions. The payer (global donors, national governments and private out-of-pocket) and procurer (supranational, national and sub-national) environment for LMIC markets is complex, heterogeneous across therapeutic categories, and is also rapidly-changing/evolving. Companies find it increasingly difficult to navigate this environment. Global market access teams have to learn new techniques and skills to understand this multi-stakeholder environment. This course brings together a faculty team with vast and rich experience in the theory and practice of access to medicines to help navigate/make decisions to be successful in LMIC markets. While grounded in strong theory, the course will use case studies and practical examples as a pedagogical approach. The high profile of the international experts and the faculty involved in the course will ensure a highly interactive and rewarding learning environment.
- Deep understanding of the payer landscape for products with supranational payers (Global Fund, Global Alliance for Vaccines and Immunization (GAVI), Global Financing Facility (GFF), StopTB’s Global Drug Facility (GDF):
- Deep understanding of the nature of procurement processes and market-shaping strategies used by supranational payers to promote access
- Deep understanding of the payers for therapeutic categories which are paid for national governments, private insurers and out-of-pocket payments in LMICs
- Familiarity with the in-country procurement eco-system in LMICs
- Understanding the architecture of drug and medical device regulation in LMICs, supranational e.g. World Health Organization, Eurasian Conformity Mark vs national Food & Drug Administrations. Also, different groups e.g. Global Harmonization Task Force (GHTF)
- Designing successful route to market strategies for products in LMICs
- Modalities for an effective engagement with key market access stakeholders and how to address possible conflicts of interests.
- Understanding the structure of medicine distribution in LMICs and how it differs from high-income markets
- Case studies of successful public partnerships to improve distribution reach
- Innovative distribution models and opportunities to disrupt the distribution market
- Provide participants with the concepts, tools, lingo and insights that will foster stronger communication with counterparts working in global agencies and LMIC country governments
- Comprehend the opportunities and pitfalls of using tiered pricing in LMICs
- Understand health technology assessment, pricing and reimbursement approaches used in LMICs
- Organizational design for success in LMICs
- Address project management capacities issues.
Curriculum Vitae Monica Otto is SDA Professor of Public Management and Policy. At SDA Bocconi, she was the Director of the Master in Public Management (2010-2013 and of the Executive Master of Management in International Organizations (2015-2016). She coordinated the Pharmaceutical Observatory a...
Prashant Yadav is a globally recognized scholar in the area of healthcare supply chains. He is the author of many peer-reviewed scientific publications and his work has also been featured in prominent print and broadcast media including The Economist, The Financial Times, Nature, and BBC. Outsid...
Viviana Mangiaterra is SDA Associate Professor of Practice. Her collaboration with SDA Bocconi began in January 2019. She is a dedicated professional with a global career in international public health. Main focus of her work has been on strategic planning; policy development; health system stren...
Brenda Waning is the Chief of the Stop TB Partnership’s Global Drug Facility (GDF) – the world’s largest supplier of tuberculosis medicines and diagnostics for the public sector. Waning is a leading expert with more than 20 years of experience in promoting access to medicines in low-resource sett...
Videos and materials
Because of COVID-19, many providers are cancelling or postponing in-person programs or providing online participation options.
We are happy to help you find a suitable online alternative.